Medical Device Skin Sensitization Testing: Determination of Sensitization Reactions per ISO 10993-10

Skin sensitization testing is an essential biocompatibility study that determines whether medical device materials can induce delayed-type hypersensitivity reactions following skin, mucosal, or internal contact. This article explains the applicable standards, sample preparation, test methods, and regulatory applications of sensitization determination for medical devices in accordance with ISO 10993-10 and GB/T 16886.10, as performed by accredited third-party laboratories.

Technical Overview

Sensitization, also known as allergic contact dermatitis, is a Type IV delayed hypersensitivity reaction mediated by T lymphocytes. When low-molecular-weight substances leaching from a medical device penetrate the skin or mucosa, they may bind to carrier proteins and act as haptens, priming the immune system. Upon repeated exposure, a sensitized individual can develop erythema, edema, pruritus, and vesiculation, which may persist even at very low exposure levels.

The determination of sensitization skin reactions is therefore a mandatory component of the biological evaluation of medical devices specified in ISO 10993-1, with detailed test procedures defined in ISO 10993-10 (Biological evaluation of medical devices — Part 10: Tests for skin sensitization). In China, the equivalent national standard is GB/T 16886.10. The evaluation follows a risk-based approach that considers the nature and duration of body contact, the materials of construction, and existing toxicological data, and is typically conducted by accredited third-party laboratories under GLP-compliant conditions.

• Evaluates delayed-type (Type IV) hypersensitivity potential of device materials and extracts
• Required for devices with skin, mucosal, or internal tissue contact
• Conducted per ISO 10993-10 and GB/T 16886.10 with samples prepared per ISO 10993-12
• Supports regulatory submissions in the United States, the European Union, China, and Japan

Testing Samples

Polar and Non-Polar Extracts

For most devices, test samples are prepared as extracts according to ISO 10993-12. Duplicate extractions are performed using a polar solvent (physiological saline or cell culture medium) and a non-polar solvent (sesame oil or cottonseed oil). Standard extraction conditions include 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, using a ratio of 3 cm² of surface area or 0.2 g of material per milliliter of solvent.

Direct Contact Materials

For the Buehler closed-patch test, solid materials or finished device components may be applied directly to intact skin. Samples are cut to a defined size and hydrated with a suitable vehicle to ensure adequate dermal contact during both the induction and challenge phases.

Sample Considerations

• Representative finished devices, components, or material coupons from the sterilized, final production condition
• Adhesives, curing agents, plasticizers, colorants, and residual process chemicals evaluated as potential sensitizers
• Extraction ratios and conditions documented and scientifically justified for small or irregular devices
• Sterility and handling requirements maintained where clinically relevant

Testing Items

The core test item is the sensitization potential of the medical device or its extracts, expressed as the incidence and severity of delayed cutaneous reactions in treated animals compared with appropriate controls. The study evaluates:

• Induction of sensitization following repeated exposure during the induction phase
• Elicitation of skin reactions after a rest period during the challenge phase
• Grading of erythema and edema on the Magnusson–Kligman scale (0 to 3)
• Lymphocyte proliferation response where the local lymph node assay is applied
• General clinical observations, body weight changes, and any adverse findings throughout the study

Testing Methods

Guinea Pig Maximization Test (GPMT)

The GPMT is the most sensitive in vivo method and is preferred for devices with prolonged, mucosal, or internal contact. The procedure includes intradermal induction with the test extract together with Freund's Complete Adjuvant, followed by topical induction approximately one week later. After a two-week rest period, a challenge patch is applied to a naive skin site, and reactions are graded at 24, 48, and 72 hours. A Magnusson–Kligman grade of 1 or greater in the test group, with unaffected negative controls, indicates a sensitization response.

Buehler Closed-Patch Test

The Buehler test uses repeated topical applications under occlusive patches and is suitable for devices intended for intact skin contact because it mimics the clinical exposure route. Three induction exposures are performed over approximately three weeks, followed by a rest period and a challenge application. Erythema and edema are scored using the standard grading scale at defined observation intervals.

Murine Local Lymph Node Assay (LLNA)

The LLNA measures antigen-specific T-cell proliferation in the draining auricular lymph nodes after topical application of the test article to the ears of mice. A stimulation index of 3 or greater identifies a potential sensitizer. The method shortens the study duration and reduces animal burden, and non-radioactive variants such as the BrdU-ELISA version align with OECD Test Guideline 442B.

In Vitro and Integrated Approaches

Defined approaches combining the direct peptide reactivity assay (OECD TG 442C) and keratinocyte reporter assays (OECD TG 442D) are increasingly used for screening. Together with chemical characterization and toxicological risk assessment, they may support a weight-of-evidence justification within the biological evaluation framework of ISO 10993-1 and ISO 10993-2, reducing or avoiding animal testing where scientifically valid.

Applications

Sensitization data form part of the biological evaluation report required in regulatory submissions across major markets, including FDA 510(k) and PMA applications, CE marking technical documentation under the EU MDR, NMPA registration in China, and submissions to Japanese regulatory authorities. Typical product categories and use cases include:

• Surface devices: adhesive bandages, wound dressings, ECG electrodes, compression garments, and prosthetic liners
• External communicating devices: intravenous catheters, infusion sets, extension tubing, endotracheal tubes, and urinary catheters
• Implantable devices: stents, orthopedic implants, cardiac leads, and absorbable scaffolds
• Change control: new raw material suppliers, formulation changes, alternative sterilization methods, and periodic re-evaluation of legacy devices

FAQ

Which standard governs medical device sensitization testing?

ISO 10993-10:2021 specifies the test methods and is harmonized with the Chinese national standard GB/T 16886.10. Test sample preparation follows ISO 10993-12, and the overall evaluation plan is defined by ISO 10993-1.

Can sensitization testing be waived?

Yes, when a documented biological evaluation demonstrates that all constituent materials have a proven history of safe use in equivalent devices with identical contact types, or when chemical characterization and toxicological risk assessment show that no leachable sensitizer is present at a level of toxicological concern. The waiver rationale must be recorded in the biological evaluation file.

How many animals are used, and how long does the study take?

A GPMT typically uses ten test animals and five controls, while a Buehler study commonly uses twenty test and ten or more control animals. Guinea pig studies generally require six to eight weeks from dose-range finding through the final report, whereas the LLNA offers a shorter schedule with fewer animals.

Why are both polar and non-polar extracts tested?

Different sensitizing leachables dissolve in solvents of different polarity. Evaluating both a polar and a non-polar extract ensures comprehensive coverage of hydrophilic and lipophilic substances that could migrate from the device during clinical use.